All studies
RecruitingHuman Pharmacology (Phase I)- First administration to humansInterventional

FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS

This is a Phase 1 clinical trial testing a new experimental medicine, IPH5301, in humans for the first time. The study is for adults with advanced solid tumours that have spread or cannot be removed by surgery. This includes cancers of the breast, stomach, food pipe (oesophagus), pancreas, womb lining, ovary, and lung. Because this is a 'first-in-human' study, the main goal is to find out if the drug is safe, what side effects it causes, and what dose works best. In some groups, the drug will be given on its own. In other groups, especially those with certain types of breast cancer, it will be combined with standard cancer medicines such as chemotherapy and trastuzumab. Taking part involves regular hospital visits for treatment, blood tests, and scans to closely monitor your health.

At a glance

Status
Recruiting
Phase
Human Pharmacology (Phase I)- First administration to humans
Sponsor
Institut Paoli-Calmettes
Enrolment target
25
Start
02 Aug 2023

What is this study about?

This clinical trial is testing a new experimental drug called IPH5301. It is a 'Phase 1' study, which means this is the very first time this medicine is being given to people. When cancer reaches an advanced stage or spreads to other parts of the body (metastatic cancer), standard treatments may stop working as well as doctors would like. Researchers are constantly looking for new ways to help the body fight these tumours.

IPH5301 is designed to help the immune system recognise and attack cancer cells. In this trial, doctors want to see how the human body handles the medicine. They will test it in two main ways: either on its own, or combined with existing cancer treatments such as chemotherapy and a targeted drug called trastuzumab. Combining treatments can sometimes make cancer therapies more effective.

The trial focuses on several types of advanced solid tumours, including cancers of the breast, stomach, gullet (oesophagus), pancreas, womb (endometrium), ovaries, and lungs. A special part of the study also looks specifically at people with breast cancer that has a protein called HER2 on the surface of the tumour cells.

Because this is an early study, the main focus is not yet on how well the drug shrinks tumours, but rather on finding a safe dose and understanding its side effects. The results will help doctors decide if IPH5301 should move forward into larger studies in the future.

Key takeaways

  • Testing a brand new cancer medicine (IPH5301) in people for the first time.
  • Aimed at adults with advanced or metastatic solid cancers, including breast, stomach, and lung.
  • Focuses on checking the safety, side effects, and best dose of the drug.
  • Involves treatment through a drip, along with regular hospital visits, blood tests, and scans.
  • Participation is entirely voluntary and you can withdraw at any time.

Who may be eligible?

This trial is open to adults aged 18 and over who have been diagnosed with an advanced or metastatic solid cancer. This means the cancer has grown into nearby tissues or spread to other parts of the body. The cancers being studied include breast, stomach, oesophagus, pancreas, womb, ovary, or lung cancer.

One part of the trial is specifically for people with breast cancer that is either 'HER2-positive' or 'HER2-low'. These are labels doctors use to describe tumours that produce a specific protein on their cells. You will usually need to have already tried standard treatments for your cancer before considering this trial.

To be eligible, you must be well enough to carry out basic daily activities and attend regular hospital appointments. People who take part will also need to have healthy heart, liver, and kidney function, which will be checked using standard blood and diagnostic tests before joining.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with advanced or metastatic solid cancer (such as breast, stomach, lung, or ovarian cancer).
  3. Standard treatments are no longer working or suitable for me.
  4. I am well enough to look after myself and travel to hospital appointments.
  5. I am willing to undergo regular scans, blood tests, and hospital visits.
Answer every question to see your result.

What does participation involve?

Taking part in this trial involves receiving IPH5301 through a drip into a vein (an intravenous infusion) at a hospital clinic. Depending on which group you join, you may receive the new drug on its own or alongside chemotherapy and trastuzumab. You will need to visit the hospital regularly for your treatments and check-ups. During these visits, the medical team will carry out physical examinations, check your vital signs, take blood and urine samples, and monitor your heart with tests like an ECG. You will also have regular imaging scans, such as CT or MRI scans, to see how your tumour is responding. You can expect to stay on the trial for as long as the treatment is helping you and the side effects are manageable, though you can choose to stop at any point.

Potential risks and benefits

Because IPH5301 is being given to humans for the first time, not all side effects are known yet. You might experience mild side effects like tiredness or sickness, but there is also a risk of more serious, unexpected reactions. The treatment might help control your cancer, but there is no guarantee that you will personally benefit from taking part. However, your participation will provide vital information that could help future cancer patients. Taking part is completely voluntary, and you are free to leave the trial at any time without it affecting your ongoing NHS care.

Locations (2)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    France
  • —
    Unverified
    Belgium

Common questions

What does a 'first-in-human' trial mean?

It means this is the very first time this specific medicine is being tested in people. Before this, it was only tested in laboratory settings.

Will I have to pay to take part in this trial?

No. The trial medication and all tests related to the study are provided free of charge.

How is the study medication given?

The medicine is given directly into your bloodstream through a drip, usually in a hospital day unit.

Can I leave the study if I change my mind?

Yes, you can leave the study at any time for any reason. Your regular doctors will support you and discuss other treatment options.

Will this drug cure my cancer?

This study is an early-stage safety trial, so a cure is not expected. The main goal is to find out if the drug is safe and to find the right dose for future testing.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Interested in taking part?

Register your interest

Share your details and the research team for "FIRST-IN-HUMAN STUDY OF IPH5301 TREATMENT ALONE OR IN COMBIN…" will contact you if you may be eligible. Always speak to your GP before agreeing to take part.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.